We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| N4 Pharma Plc | N4P | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| -0.025 | -4.17% | 0.575 | 10:27:50 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 0.60 | 0.575 | 0.60 | 0.575 | 0.60 |
| Industry Sector |
|---|
| PHARMACEUTICALS & BIOTECHNOLOGY |
| Top Posts |
|---|
Posted at 23/11/2024 09:37 by pwal Tweet:The @humancellatlas is transforming our understanding of health and disease. With newly uncovered cell types, including those linked to inflammation in #IBD, advanced therapies targeting specific cells such as Nuvec®, will be more in demand: bbc.co.uk/news/artic |
Posted at 11/11/2024 13:49 by pwal Who thinks N4P can hit 1p before the end of the year? |
Posted at 25/10/2024 12:28 by fido People should take a look at the PDF.In it the company clearly states that the upside from here is 20-50 times which would value N4P at more than 100 million. |
Posted at 24/10/2024 08:35 by pwal Well I guess now is the time to stock up on N4P. But it will be a slow burner.The Company's aim is to advance preclinical studies and prepare for a Clinical Trial Authorisation ("CTA") / Investigational New Drug ("IND") filing in the coming years |
Posted at 10/10/2024 07:08 by pwal Come on N4P! |
Posted at 05/10/2024 06:17 by earwacks No shortage of anguish for shareholders of N4P. It all still looks very plausible if a bit stretched. Certainly they have a product that if proven to be as beneficial as it sounds should be mega. Looks like the hard miles have been virtually done, just a little good fortune needed. |
Posted at 20/8/2024 07:20 by pwal Keep the news coming N4P! |
Posted at 19/7/2024 09:11 by pwal So what's happening next with N4P? |
Posted at 18/4/2024 06:09 by jakleeds 18 April 2024N4 Pharma plc ("N4 Pharma" or the "Company") Oral Delivery Update N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, is pleased to provide a further positive update on its ongoing oral delivery research work. The Company, through its research program with the University of Queensland, has undertaken further testing, in vivo, to show the successful delivery of a Nuvec® capsule into the intestine where it has released its plasmid DNA payload to produce localised protein expression. This work further demonstrates the potential of Nuvec® as an oral delivery system for multiple nucleotide payloads. Specifically, in this experiment an enterically coated capsule containing PEGylated Nuvec® loaded with a plasmid DNA expressing ovalbumin was administered on day 0 and subsequent capsules on day 3, day 6, day 9 and a booster capsule at day 21. Protein expression was significantly higher than control (DNA alone and non-PEGylated DNA loaded Nuvec®) up until day 25 which subsequently dropped away by day 36. In addition, a significantly higher ovalbumin antibody response was measured at day 36 in the PEGylated Nuvec® sample compared to control. Nigel Theobald, Chief Executive Officer of the Company, commented: "This work once more clearly shows that Nuvec® has the potential to be developed as an oral delivery system for plasmid DNA, mRNA or siRNA with many potential applications such as a vaccination with plasmid DNA or to deliver a local product for Irritable Bowel Disease or to treat colonic cancer among many possible examples. "We will continue to scope out the work needed to explore a potential development program focusing on a specific oral application and further news on this will be announced when a program is identified. In the meantime, the University of Queensland will continue its work as part of our ARC funded grant with them." For more information please contact: N4 Pharma plc Nigel Theobald, CEO Luke Cairns, Executive Director Engage with us directly at N4 Pharma Investor Hub |
Posted at 23/2/2024 07:22 by nobbygnome Pharma/biotech don’t take risks. The chances are they will wait for all the pre clinical work to be completed before they even contemplate a deal. Just imagine the poor guy who advocates signing the deal….and then it fails in a tox study. He will have serious egg on his face and his career will be blighted.N4P is desperate for cash and there really is no rush for Pharma to do a deal. Just wait for the N4P price to slump as another fund raise comes along… |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
